Combined Chemo- and Photothermal Therapies of Non-Small Cell Lung Cancer Using Polydopamine/Au Hollow Nanospheres Loaded with Doxorubicin

被引:3
|
作者
Zhang, Xinbo [1 ]
Xu, Bin [1 ]
Ni, Jiangwei [1 ]
Xiang, Yucheng [1 ]
He, Zhifeng [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Wenzhou, Zhejiang, Peoples R China
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2024年 / 19卷
关键词
non-small cell lung cancer; chemotherapy; photothermal therapy; doxorubicin; Au nanoparticles; NANOPARTICLES; ATLANTIS;
D O I
10.2147/IJN.S473137
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Purpose: The chemotherapeutic agent doxorubicin (DOX) is limited by its cardiotoxicity, posing challenges in its application for nonsmall cell lung cancer (NSCLC). This study aims to explore the efficacy of polydopamine/Au nanoparticles loaded with DOX for chemotherapy and photothermal therapy in NSCLC to achieve enhanced efficacy and reduced toxicity. Methods: Hollow polydopamine (HPDA)/Au@DOX was synthesized via polydopamine chemical binding sacrificial template method. Morphology was characterized using transmission electron microscopy, particle size and potential were determined using dynamic light scattering, and photothermal conversion efficiency was assessed using near-infrared (NIR) thermal imaging. Drug loading rate and in vitro drug release were investigated. In vitro, anti-tumor experiments were conducted using CCK-8 assay, flow cytometry, and live/dead cell staining to evaluate the cytotoxicity of HPDA/Au@DOX on A549 cells. Uptake of HPDA/Au@DOX by A549 cells was detected using the intrinsic fluorescence of DOX. The in vivo anti-metastasis and anti-tumor effects of HPDA/ Au@DOX were explored in mouse lung metastasis and subcutaneous tumor models, respectively. Results: HPDA/Au@DOX with a particle size of (164.26 +/- 3.25) nm, a drug loading rate of 36.31%, and an encapsulation efficiency of 90.78% was successfully prepared. Under 808 nm laser irradiation, HPDA/Au@DOX accelerated DOX release and enhanced uptake by A549 cells. In vitro photothermal performance assessment showed excellent photothermal conversion capability and stability of HPDA/Au@DOX under NIR laser irradiation. Both in vitro and in vivo experiments demonstrated that the photothermalchemotherapy combination group (HPDA/Au@DOX+NIR) exhibited stronger anti-metastatic and anti-tumor activities compared to the monotherapy group (DOX). Conclusion: HPDA/Au@DOX nanosystem demonstrated excellent photothermal effect, inhibiting the growth and metastasis of A549 cells. This nanosystem achieves the combined effect of chemotherapy and photothermal, making it promising for NSCLC treatment.
引用
收藏
页码:9597 / 9612
页数:16
相关论文
共 50 条
  • [41] The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy
    Shen, Jia
    Song, Guosheng
    An, Man
    Li, Xianqian
    Wu, Ning
    Ruan, Kangcheng
    Hu, Junqing
    Hu, Ronggui
    BIOMATERIALS, 2014, 35 (01) : 316 - 326
  • [42] Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer
    Rivera-Concepcion, Joel
    Uprety, Dipesh
    Adjei, Alex A.
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 315 - 329
  • [43] Immune-based Therapies for Non-small Cell Lung Cancer
    Rafei, Hind
    El-Bahesh, Ehab
    Finianos, Antoine
    Nassereddine, Samah
    Tabbara, Imad
    ANTICANCER RESEARCH, 2017, 37 (02) : 377 - 387
  • [44] Targeted therapies and radiation therapy in non-small cell lung cancer
    Rivera, S.
    Quero, L.
    Kam, S. Wong Hee
    Maylin, C.
    Deutsch, E.
    Hennequin, C.
    CANCER RADIOTHERAPIE, 2011, 15 (6-7): : 527 - 535
  • [45] Molecularly-targeted therapies for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2667 - 2679
  • [46] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Patrick R. Halliday
    Collin M. Blakely
    Trever G. Bivona
    Current Oncology Reports, 2019, 21
  • [47] Targeted therapies in combination with chemotherapy in non-small cell lung cancer
    Johnson, David H.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4451S - 4457S
  • [48] Targeting novel and established therapies for non-small cell lung cancer
    Spicer, James
    Chowdhury, Simon
    Harper, Peter
    CANCER LETTERS, 2007, 250 (01) : 9 - 16
  • [49] Targeted/Emerging Therapies for Metastatic Non-Small Cell Lung Cancer
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 676 - 678
  • [50] Complications following novel therapies for non-small cell lung cancer
    Skribek, Marcus
    Rounis, Konstantinos
    Tsakonas, Georgios
    Ekman, Simon
    JOURNAL OF INTERNAL MEDICINE, 2022, 291 (06) : 732 - 754